Model Number IMMULITE 2000 IGF-1 (RE-STANDARDIZED) |
Device Problems
Labelling, Instructions for Use or Training Problem (1318); Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problem
No Known Impact Or Consequence To Patient (2692)
|
Event Date 06/13/2017 |
Event Type
malfunction
|
Manufacturer Narrative
|
The customer contacted a siemens customer care center.The customer believes that the issue was with patient sample.The cause of the discordant, falsely low igf-1 (re-standardized) result on one patient sample is unknown.Siemens is investigating the issue.
|
|
Event Description
|
The customer obtained a discordant, falsely low insulin-like growth factor i (re-standardized) result on one patient sample on an immulite 2000 xpi instrument, when using reagent kit lot 116.The sample was tested on an alternate platform, resulting higher.The initial result was not reported to the physician(s).The result obtained on the alternate platform was reported to the physician(s).There are no reports of patient intervention or adverse health consequence due to the discordant, falsely low igf-1 (re-standardized) result.
|
|
Manufacturer Narrative
|
The initial mdr was filed on july 14, 2017.Additional information (08/25/2017): a siemens headquarters support center specialist reviewed the event data and determined that for sample id (b)(4), result obtained on the immulite 2000 xpi instrument matched the clinical interpretation of the result obtained on an alternate platform.Siemens healthcare diagnostics internal investigation has confirmed that immulite systems insulin-like growth factor i instructions for use reference ranges are inappropriate as statistically calculated in the current instructions for use.Mdrs 2432235-2017-00385 and 2432235-2017-00424 were filed for the same event.
|
|
Manufacturer Narrative
|
The initial mdr 2432235-2017-00420 was filed on (b)(6) 2017.The first supplemental mdr 2432235-2017-00420_s1 was filed on (b)(6) 2017.Additional information (11/02/2017): the customer contacted a siemens customer care center and stated that they have been testing samples for insulin-like growth factor i (igf-1) on immulite system without further issues.The customer has been using new reference ranges to interpret igf-1 results.
|
|
Manufacturer Narrative
|
The initial mdr 2432235-2017-00420 was filed on 14-jul-2017.The first supplemental mdr 2432235-2017-00420_s1 was filed on 13-sep-2017.The second supplemental mdr 2432235-2017-00420_s2 was filed on 27-nov-2017.The third supplemental mdr 2432235-2017-00420_s3 was filed on dec-12-2017.Additional information (20-nov-2017): updated to align with the information provided in third supplemental mdr 2432235-2017-00420_s3 filed on dec-12-2017.
|
|
Manufacturer Narrative
|
(b)(4).Additional information (20-nov-2017): siemens investigated alternate statistical methods to evaluate the reference range data published in the instructions for use (ifu) and determined if an alternate method would provide a more robust fit for the data.Our investigation concluded that the lms (statistical smoothing method to re-evaluate the original ifu data) provided a better fit to the data and produced ranges consistent with the expected physiological change in insulin-like growth factor i (igf-i) levels compared to use of the weighted average results reported in the ifu.The current immulite systems igf-1 ifu expected values are computed using a weighted average of ordered data points near the specified percentile.Computing the expected values using the lms method, a centile smoothing method, generates ranges that are more appropriate for diagnostic use.Customer notification "insulin-like growth factor i (igf-1) revised reference ranges" imc18-03.A.Ous was sent to the ous customers and imc18-03.A.Us was sent to the us customers in november 2017.Mdrs 2432235-2017-00385_s4 and 2432235-2017-00424_s3 were filed for the same event.
|
|
Search Alerts/Recalls
|